论文部分内容阅读
[目的]探讨分析OLFIRI方案及XELOX方案在胃癌治疗中的临床疗效及不良反应。[方法]回顾性分析2009年6月1日~2013年12月1日期间在我院接受治疗的胃癌的患者70例将患者分成治疗组和对照组,其中对照组35例采用滴注伊立替康、亚叶酸钙和氟尿嘧啶的FOLFIRI方案治疗,治疗组35例采用奥沙利铂联合卡培他滨的XELOX方案治疗,观察比较两种治疗方法的临床疗效及不良反应。[结果]2组患者经治疗后发现,治疗组的总有效率(65.71%)和对照组的总有效率(71.42%)无明显差异,差异无统计学意义(P>0.05);治疗组的不良反应发生率(12.00%)明显低于对照组(45.71%),差异有统计学意义(P<0.05),差异有统计学意义(P<0.05)。[结论]XELOX疗法和OLFIRI疗法对胃癌患者的治愈率无明显差异,但XELOX方案在胃癌治疗中减少了患者不良反应的发生,值得在临床上推广使用。
[Objective] To investigate the clinical efficacy and adverse reactions of OLFIRI regimen and XELOX regimen in the treatment of gastric cancer. [Methods] A total of 70 patients with gastric cancer treated in our hospital from June 1, 2009 to December 1, 2013 were retrospectively analyzed. Patients in the control group were divided into treatment group and control group. Kang, leucovorin and fluorouracil FOLFIRI regimen, the treatment group of 35 patients treated with oxaliplatin combined with capecitabine XELOX regimen, the clinical efficacy and adverse reactions of the two treatment methods were observed and compared. [Results] After treatment, the two groups showed no significant difference in the total effective rate (65.71%) and the control group (71.42%), the difference was not statistically significant (P> 0.05) The incidence of adverse reactions (12.00%) was significantly lower than that of the control group (45.71%), the difference was statistically significant (P <0.05), the difference was statistically significant (P <0.05). [Conclusion] There is no significant difference between XELOX and OLFIRI in the cure rate of gastric cancer patients. However, XELOX regimen reduces the incidence of adverse reactions in patients with gastric cancer and is worth popularizing in clinic.